Hepatitis A Vaccines (Hepatitis A Vaccine)

01/01/2009 - "Hepatitis A vaccines have been highly effective in preventing hepatitis A. "
10/25/2007 - "Hepatitis A vaccine administered to persons after exposure to the hepatitis A virus has not been compared directly with immune globulin, which is known to be highly effective in preventing hepatitis A when given within 2 weeks after exposure to the virus. "
02/01/2004 - "Improved understanding of the epidemiology and transmission of hepatitis A combined with the availability of effective hepatitis A vaccines have dramatically reduced the burden of hepatitis A in the United States."
08/13/1992 - "The inactivated purified hepatitis A vaccine that we tested is well tolerated, and a single dose is highly protective against clinically apparent hepatitis A."
10/29/2014 - "Benefiting from the booming economy, rapid improvement in sanitation, safe water supply, and implementation of hepatitis A vaccines, the epidemiological pattern of hepatitis A moved from high to intermediate endemicity in Shijiazhuang. "

11/01/1998 - "The recent availability and proven efficacy of a hepatitis A vaccine offers the hope that the incidence of infection may be substantially reduced. "
04/03/1999 - "Hepatitis A vaccine is effective in the prevention of secondary infection of HAV and should be recommended for household contacts of primary cases of HAV infection."
03/21/2001 - "A randomised controlled trial of hepatitis A vaccine in household contacts of people with sporadic HAV infection in Italy has shown a protective efficacy of 82% (CI 20-96%). "
12/01/1995 - "Immunization with inactivated hepatitis A vaccine is a safe and effective method for travelers to endemic areas to protect themselves against this infection."
03/01/1998 - "Two new inactivated hepatitis A vaccines are available that confer long-term protection against infection. "

12/07/2006 - "Hepatitis A vaccine is both safe and effective in this small studied group of children with chronic liver disease. "
12/07/2006 - "To study the safety and efficacy of hepatitis A vaccine (HAV) in children with chronic liver disease of various etiologies. "
12/07/2006 - "Safety and efficacy of hepatitis A vaccine in children with chronic liver disease."
06/01/1997 - "Thus, an inactivated hepatitis A vaccine was safe in patients with chronic liver disease while the immune response was inferior to that observed in healthy subjects reported in a previous study."
04/01/2009 - "Hepatitis A vaccine is not required in adult patients with chronic liver disease in Saudi Arabia."

05/01/1995 - "Inactivated hepatitis A vaccines appear to be highly effective in preventing clinical hepatitis and controlling epidemics. "
06/22/2015 - "Our study suggests that the introduction of two-dose hepatitis A vaccines in Panama has contributed to the reduction in the incidence of overall hepatitis-related outcomes for all age groups, suggesting herd protection. "
07/24/2015 - "Improvements in water quality and sanitation as well as inclusion of hepatitis A vaccine in childhood immunization programs should be considered to reduce the public health burden of hepatitis in India. "
05/01/2009 - "The series of coincidences that led to my involvement in the field of viral hepatitis and the circuitous pathway leading to the development of the first hepatitis A vaccine is described from a personal perspective."
01/01/2006 - "Long-term protective effect of post-exposure Havrix administration during viral hepatitis Type A outbreaks."

12/01/2006 - "The hepatitis A vaccine was found to be effective and safe in children with cancer."
12/01/2006 - "Immunogenicity of hepatitis a vaccine in children with cancer."
12/01/2006 - "This study evaluated the immuned response of the hepatitis A vaccine in children with cancer who were receiving chemotherapy. "
05/01/2009 - "A pooled analysis of the safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine Cervarix (GlaxoSmithKline) was performed in a cohort of almost 30,000 girls and women aged > or =10 years, 16,142 who received at least one dose of the HPV-16/18 vaccine and 13,811 who received one of three controls [Al(OH)(3) or hepatitis A vaccine (720 or 360 EU)]. "